IsoRay names new CFO, plans to file for Amex listing

By Elaine Rigoli

Tampa, Fla., Sept. 11 - IsoRay, Inc. has appointed Jonathan Hunt, formerly its controller, as the company's chief financial officer.

Hunt is succeeding Michael Dunlop, who is considering a new position as vice president of planning and facilities with responsibility for opening and managing IsoRay's new manufacturing facilities in Idaho.

IsoRay also announced its intent to file for a listing on the American Stock Exchange within the next month.

Effective Oct. 1, the price paid by customers for IsoRay's Cesium-131 brachytherapy seed will increase to $59.00 per seed from its current price of $55.00. Management is also pursuing discussions to expand into Europe, Russia and Asia.

Based in Richland, Wash., IsoRay, through its subsidiary, IsoRay Medical, Inc., is the sole producer of the Cesium-131 brachytherapy seed, used to treat prostate and other cancers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.